Experiment Design: Anti-Tau Therapy Failure Mechanism in Progressive Supranuclear Palsy
Executive Summary
flowchart TD
PSP["PSP"] -->|"associated with"| Alzheimer["Alzheimer"]
PSP["PSP"] -->|"associated with"| Als["Als"]
PSP["PSP"] -->|"associated with"| Alzheimer_s_disease["Alzheimer's disease"]
PSP["PSP"] -->|"expressed in"| neurons["neurons"]
PSP["PSP"] -->|"downregulates"| SV2A["SV2A"]
PSP["PSP"] -->|"targets"| tauopathy["tauopathy"]
PSP["PSP"] -->|"participates in"| unfolded_protein_response["unfolded protein response"]
PSP["PSP"] -->|"regulates"| STX6["STX6"]
PSP["PSP"] -->|"associated with"| frontotemporal_dementia["frontotemporal dementia"]
PSP["PSP"] -->|"participates in"| oxidative_stress_response["oxidative stress response"]
PSP["PSP"] -->|"associated with"| Parkinson_s_disease["Parkinson's disease"]
PSP["PSP"] -->|"regulates"| Parkinson_s_disease["Parkinson's disease"]
PSP["PSP"] -->|"associated with"| tauopathy["tauopathy"]
PSP["PSP"] -->|"biomarker for"| Ms["Ms"]
style PSP fill:#4fc3f7,stroke:#333,color:#000
This experiment addresses the critical knowledge gap: "Why have anti-tau therapies failed in PSP despite strong biological rationale?" (Rank #10, PSP Knowledge Gaps). Multiple anti-tau antibody trials have failed in PSP, including gosuranemab (TANGOS) and tilavonemab, despite compelling preclinical data. This experiment will systematically investigate the mechanisms of these failures to inform next-generation therapeutic development.
Hypothesis
...Experiment Design: Anti-Tau Therapy Failure Mechanism in Progressive Supranuclear Palsy
Executive Summary
Mermaid diagram (expand to render)
This experiment addresses the critical knowledge gap: "Why have anti-tau therapies failed in PSP despite strong biological rationale?" (Rank #10, PSP Knowledge Gaps). Multiple anti-tau antibody trials have failed in PSP, including gosuranemab (TANGOS) and tilavonemab, despite compelling preclinical data. This experiment will systematically investigate the mechanisms of these failures to inform next-generation therapeutic development.
Hypothesis
Anti-tau antibody failures in PSP result from one or more of the following mechanisms:
Wrong target: Antibodies target epitopes not primarily involved in 4R-tau pathogenic spreading
Wrong compartment: Extracellular antibodies fail to reach intracellular tau where pathology initiates
Wrong timing: Treatment begins too late in disease progression when neurodegeneration is irreversible
Wrong mechanism: Antibodies clear tau without addressing upstream drivers of 4R-tau productionPrimary Objectives
Characterize tau species in PSP patient CSF and brain tissue — determine which tau fragments are pathogenic and whether current antibodies target them
Map tau distribution in PSP brain — compare extracellular vs. intracellular tau, and neuron vs. oligodendrocyte tau
Test whether anti-tau antibodies can engage pathological tau in PSP brain — ex vivo binding studies
Identify biomarkers predicting anti-tau therapy response — develop patient stratification toolsStudy Design
Phase 1: PSP Brain Tissue Analysis
Sample: Post-mortem brain tissue from 20 PSP patients (Richardson's syndrome, PSP-P variants) and 10 age-matched controls
Analyses:
- Sequential extraction (RIPA, formic acid) to separate soluble, membrane-bound, and insoluble tau fractions
- SDS-PAGE and western blot to characterize tau isoforms (4R vs. 3R/4R ratio)
- ELISA for specific tau fragments (N-terminal, mid-domain, C-terminal, phosphorylated at Ser202, Thr181, Ser396/404)
- immunohistochemistry for tau distribution (neuronal, oligodendroglial, extracellular)
- Electron microscopy for tau filament structure
Expected output: Detailed tau species catalog in PSP brain
Phase 2: Antibody Epitope Mapping
Antibodies to test:
- Gosuranemab (N-terminal anti-tau)
- Tilavonemab (mid-domain anti-tau)
- Semorinemab (central domain)
- E2814 (MTBR-domain, in clinical trials)
- Posdinemab (phospho-tau specific)
Method:
- Dot blot with synthetic tau peptides spanning full-length tau
- Surface plasmon resonance (SPR) for binding kinetics
- Cryo-EM to visualize antibody-FAB binding to PSP-derived tau filaments
- Competition assays to determine epitope overlap
Expected output: Epitope map showing which antibodies recognize which PSP tau species
Phase 3: Ex Vivo Antibody Engagement
Method:
- Incubate fresh frozen PSP brain sections with each antibody
- Image using confocal microscopy to quantify antibody penetration and binding
- Compare to antibody binding in AD brain (where antibodies have shown efficacy)
- Test whether adding permeabilization or enzymatic treatment improves binding
Expected output: Determine whether antibody access to pathological tau is a limiting factor
Phase 4: Biomarker Development
Samples: CSF and plasma from 100 PSP patients, 50 PD patients, 50 controls
Biomarkers to measure:
- Total tau, p-tau181, p-tau217, p-tau205
- NfL, GFAP
- Tau种子 (RT-QuIC or PMCA)
- Tau proteoforms (capillary electrophoresis)
Correlate with:
- Clinical severity (PSPRS, MoCA)
- Disease duration
- MRI atrophy patterns
Expected output: Biomarker panel predicting which patients might respond to which anti-tau mechanism
Model Systems
In Vitro Models
- iPSC-derived neurons from PSP patients (MAPT mutations P301S, S305I)
- iPSC-derived oligodendrocytes (relevant for coiled body pathology)
- Organoid models with 4R-tau pathology
Animal Models
- PS19 mice (P301S tau) — test antibody efficacy
- AAV-mediated 4R-tau overexpression in mice — test timing effects
- Non-human primates for translational studies
Expected Outcomes
Catalog of pathogenic tau species in PSP — enabling rational antibody design
Epitope mapping of failed and current antibodies — guiding selection of optimal targets
Mechanistic understanding of failure — whether timing, target, or compartment is the key factor
Biomarker panel for patient stratification — enabling enrichment of trials with likely respondersFeasibility Assessment
| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Mechanistic Impact | 10 | Will directly explain why billions invested in anti-tau trials failed |
| Cure Proximity | 9 | Enables rational next-generation trial design |
| Feasibility | 7 | Requires PSP brain tissue, which is available through brain banks |
| Cost Efficiency | 8 | Leverages existing failed trial materials and data |
| Timeline | 8 | Can begin within 6 months; 24-month primary analysis |
| Cross-Disease Value | 9 | Findings apply to CBD, AD, and other tauopathies |
| Biomarker Enablement | 10 | Directly enables biomarker-driven trial design |
| Combinability | 8 | Compounds with other experiments (tau spreading, oligodendrocyte function) |
| De-risking Value | 10 | Critical for avoiding another failed $500M Phase 3 trial |
| Novelty | 9 | First systematic analysis of anti-tau failure mechanisms |
Total Score: 78/100
Budget Estimate
| Component | Cost |
|-----------|------|
| Brain tissue acquisition (20 PSP, 10 control) | $50,000 |
| Biochemical analyses | $80,000 |
| Antibody testing and epitope mapping | $60,000 |
| Cryo-EM | $100,000 |
| Biomarker development (100 pts) | $70,000 |
| iPSC differentiation | $40,000 |
| Personnel (2 FTE × 2 years) | $200,000 |
| Total | $600,000 |
Timeline
| Milestone | Timepoint |
|-----------|-----------|
| Brain tissue acquired | Month 6 |
| Phase 1 complete (tau species catalog) | Month 12 |
| Phase 2 complete (epitope mapping) | Month 18 |
| Phase 3 complete (ex vivo engagement) | Month 24 |
| Phase 4 complete (biomarker panel) | Month 30 |
| Final analysis and publication | Month 36 |
Risk Mitigation
| Risk | Mitigation |
|------|------------|
| Limited PSP brain tissue availability | Partner with multiple brain banks (Mayo, UCSF, Cambridge) |
| Antibody manufacturers unwilling to share | Use publicly available data; test biosimilars |
| Findings too late for current trials | Publish interim results; engage pharma partners early |
References
[Boxer AL, et al., Safety and target engagement of gosuranemab in progressive supranuclear palsy (2023)](https://pubmed.ncbi.nlm.nih.gov/37265220/)
[Dam T, et al., Efficacy and safety of tilavonemab in PSP (TANGOS) (2023)](https://pubmed.ncbi.nlm.nih.gov/37654823/)
[Lewandowska et al., Tau-Targeting Therapies in Neurodegeneration: Lessons from Failed Trials (2022)](https://doi.org/10.1038/s41582-022-00792-4)
[Teng E, et al., Randomized Phase II Study of Semorinemab in AD: Lauriet (2022)](https://pubmed.ncbi.nlm.nih.gov/36325678/)
[Mummery CJ, et al., Tau-targeting antisense oligonucleotide MAPTRx in AD: Phase 1b trial (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)
[Kim A, et al., Bemdaneprocel (CRL) cell therapy for PD: Phase 1 results (2024)](https://pubmed.ncbi.nlm.nih.gov/38215634/)
[BIIB080 Study Group, Phase 1b long-term extension: Exploratory clinical outcomes in AD (2026)](https://pubmed.ncbi.nlm.nih.gov/41673497/)Related Pages
- [Experiment Priority Index](/experiments/experiment-priority-index)
- [4R-Tau Targeting in PSP/CBS](/experiments/4r-tau-targeting-psp-cbs)
- [Tau Spreading Network Mapping in PSP](/experiments/tau-spreading-network-mapping-psp)
- [PSP Knowledge Gaps](/gaps/progressive-supranuclear-palsy)
- [CBS/PSP Cure Roadmap](/mechanisms/cbs-psp-cure-roadmap)
Pathway Diagram
The following diagram shows the key molecular relationships involving Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Trials Have Not Succeeded discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)